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ABSTRACT: Background: As Parkinson’s disease pro-
gresses, levodopa treatment loses efficacy, partly through
the loss of the endogenous dopamine-synthesizing enzyme
L-amino acid decarboxylase (AADC). In the phase I PD-1101
study, putaminal administration of VY-AADC01, an investi-
gational adeno-associated virus serotype-2 vector for deliv-
ery of the AADC gene in patients with advanced Parkinson’s
disease, was well tolerated, improved motor function, and
reduced antiparkinsonian medication requirements.
Objectives: This substudy aimed to determine whether the
timing and magnitude of motor response to intravenous
levodopa changed in PD-1101 patients after VY-AADC01
administration.
Methods: Participants received 2-hour threshold
(0.6 mg/kg/h) and suprathreshold (1.2 mg/kg/h) levodopa
infusions on each of 2 days, both before and approximately
6 months after VY-AADC01. Infusion order was randomized
and double blinded. Unified Parkinson’s Disease Rating
Scale motor scores, finger-tapping speeds, and dyskinesia
rating scores were assessed every 30 minutes for 1 hour
before and ≥3 hours after start of levodopa infusion.
Results: Of 15 PD-1101 patients, 13 participated in the sub-
study. Unified Parkinson’s Disease Rating Scale motor score
area under the curve responses to threshold and sup-
rathreshold levodopa infusions increased by 168% and
67%, respectively, after VY-AADC01; finger-tapping speeds
improved by 162% and 113%, and dyskinesia scores
increased by 208% and 72%, respectively, after VY-
AADC01. Adverse events (mild/moderate severity) were
reported in 5 participants during levodopa infusions pre–VY-
AADC01 and 2 participants post–VY-AADC01
administration.
Conclusions: VY-AADC01 improved motor responses to
intravenous levodopa given under controlled conditions.
These data and findings from the parent study support fur-
ther clinical development of AADC gene therapy for people
with Parkinson’s disease. © 2020 The Authors. Movement
Disorders published by Wiley Periodicals, Inc. on behalf of
International Parkinson and Movement Disorder Society.
Key Words: AADC; gene therapy; levodopa;
Parkinson’s disease; VY-AADC01
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Parkinson’s disease (PD) is characterized by the pro-
gressive loss of substantia nigra dopaminergic neurons
that project to the striatum, with greater initial loss of
projections to the posterior putamen.1-4 Levodopa, the
immediate precursor of dopamine, is the most effective
treatment for the motor symptoms of PD.5,6 Synthesis of
dopamine from levodopa in nigrostriatal neurons is
mediated by the enzyme L-amino acid decarboxylase
(AADC).7,8 As disease progresses over time and AADC
levels fall,9,10 previously sufficient doses of levodopa lose
efficacy; ultimately, patients experience a less robust and
predictable levodopa response characterized by motor
fluctuations.6,9,11,12 Consequently, patients may require
higher and additional doses of levodopa and adjunct
therapies to maintain motor function. Unfortunately,
higher doses of dopaminergic therapies for PD are often
associated with dose-limiting motor (such as dyskine-
sias)13-17 and nonmotor (gastrointestinal symptoms, neu-
ropsychiatric symptoms, impulse control disorders, and
hallucinations) side effects.13,14,16-18
To address the loss of dopamine synthesis from orally
administered levodopa, the replacement of AADC enzy-
matic activity through adeno-associated viral vector
serotype-2 (AAV2)–mediated gene therapy has been inves-
tigated in preclinical models and clinical trials. Direct infu-
sion of AAV2s containing complementary DNA encoding
the human AADC enzyme (AAV2-hAADC) to the striatum
of nonhuman primates (NHPs) with 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkin-
sonism durably increased AADC activity in the striatum
and led to improved clinical rating scores in response to
low doses of levodopa that were ineffective in sham gene
therapy–treated parkinsonian NHPs.19-21 In 2 initial clini-
cal trials, conventional “blind” stereotactic administration
of AAV2-hAADC to the putamen of patients with PD was
well tolerated and led to increased enzyme activity, as
determined by 6-[18F]fluoro-L-meta-tyrosine positron emis-
sion tomography, that persisted for 4 years after sur-
gery.22-25 However, the clinical benefit observed in the
patients enrolled in these trials was limited and not durable,
possibly because of low vector infusion volumes and inade-
quate putaminal coverage.22,23,25
PD-1101 is an open-label, phase I, dose-escalation
trial of AADC gene therapy in patients with moder-
ately advanced PD utilizing intraoperative magnetic
resonance imaging–guided putaminal administration
of VY-AADC01, an AAV2 vector for the delivery of
the gene encoding the AADC enzyme. In this trial,
VY-AADC01 was well tolerated and led to increased
AADC enzyme activity (measured by 18F-fluoro-L-
dihydroxyphenylalanine positron emission tomogra-
phy). Antiparkinsonian medications requirements
decreased, patient-reported on time without trouble-
some dyskinesia increased, Unified Parkinson’s Disease
Rating Scale (UPDRS) III scores decreased, and quality
of life improved.26
Intravenous (IV) levodopa challenge has been used in
previous studies to independently and objectively evalu-
ate the effect of potential therapies on motor responses
to levodopa in people with PD.27,28 These studies quan-
tified responses to 2 different doses of levodopa in a
randomized and blinded fashion to allow for an objec-
tive assessment of clinical effects of the evaluated thera-
pies. Here we report the outcomes of a substudy of
PD-1101 in which the responsiveness to 2 different doses
of IV levodopa was examined prior to and following
VY-AADC01 administration using a blinded and ran-
domized study design. Exploiting the ability of AADC to
convert levodopa to dopamine, this gene therapy
approach was hypothesized to increase putaminal dopa-
mine availability that would consequently enhance the
duration and/or magnitude of responses to fixed doses of
levodopa, measured by motor function tests. Full
methods and interim safety and efficacy outcomes of the
PD-1101 trial have been reported previously.26
Methods
Participants
This substudy of PD-1101 was conducted at Oregon
Health & Science University (OHSU). Patients enrolled in
PD-1101 who were able to travel to OHSU participated
in this substudy. Patients eligible for inclusion in PD-1101
were aged 40 to 70 years and had PD with medically
refractory motor fluctuations, a history of responsiveness
to dopaminergic therapy, and disease duration ≥5 years;
further details on inclusion and exclusion criteria can be
found at https://clinicaltrials.gov (NCT01973543).
VY-AADC01 Dosing and Surgical
Administration
Details on preparation and surgical administration of
VY-AADC01 have been described previously.26 Briefly,
patients received bilateral intraoperative magnetic reso-
nance imaging–guided administration of the gene therapy
to the putamen using a frontal approach and ≥2 trajectories
per hemisphere. There were 3 dose cohorts: cohort 1, total
dose ≤7.5 × 1011 vector genomes in an infusion volume of
≤450 μL per putamen; cohort 2, ≤1.5 × 1012 vector
genomes in ≤900 μL; cohort 3, ≤4.7 × 1012 vector genomes
in ≤900 μL.
IV Levodopa Assessment
The protocol for IV levodopa assessment was approved
by the OHSU institutional review board, and all partici-
pants provided written informed consent. Participants
underwent IV levodopa assessment prior to and
≈6 months after administration of VY-AADC01. They
were admitted to the hospital on the day prior to first
levodopa administration and underwent baseline exami-
nation. All antiparkinsonian medications (including
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immediate and controlled-release formulations) were
withheld from 10:00 PM the night prior to assessment
until the completion of assessment on the following day.
Participants received levodopa infusions at 2 different
dose levels over 2 days, with 1 infusion per day. Infusions
were prepared as 0.6 mg/mL (threshold concentration)
and 1.2 mg/mL (suprathreshold concentration) solutions
and delivered intravenously at 1 mL/kg/h for 2 hours
each day. The order in which the 2 levodopa doses were
delivered was randomized for each participant by the
research pharmacy, and investigators and participants
were blinded to dosing. This paradigm was based on ear-
lier studies, with increased doses compared with those
used previously (0.5 mg/mL and 1.0 mg/mL, respec-
tively).27,28 The threshold dose was expected to represent
a threshold for clinical responsiveness, such that partici-
pants might receive a brief clinical benefit or none at all,
whereas the suprathreshold dose was predicted to almost
certainly elicit clinical responses. The threshold and sup-
rathreshold doses of levodopa closely resembled those
used in the aforementioned primate studies, in which
MPTP-lesioned NHPs that received AAV2-hAADC
responded to low-dose and high-dose levodopa infusions,
whereas MPTP-lesioned animals that received sham gene
therapy only responded to high-dose levodopa.20 We did
not include a placebo dose because admissions to the
clinical research unit were limited to 2 days given the tax-
ing nature of the protocol for participants; based on the
rationale noted previously, we felt the threshold and sup-
rathreshold doses of greater utility. In addition, given that
the informed consent forms would give participants prior
knowledge that 1 dose would be placebo, it was consid-
ered likely that participants would identify the placebo
dose within 15 to 60 minutes of infusion initiation, con-
founding assessment of clinical responses. Oral carbidopa
(25 mg) was administered 1 hour prior to, 1 hour after,
and 3 hours after initiation of levodopa infusion to
match the 2-hour treatment intervals often employed in
clinical use for patients with moderately advanced PD.
Starting 1 hour prior to initiation of levodopa infu-
sion, assessment of UPDRS III scores, finger-tapping
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FIG. 1. Change from baseline in UPDRS III scores over time during and following threshold and suprathreshold infusions of intravenous levodopa pre–
and post–VY-AADC01 administration. A reduction in UPDRS III scores represents improvement. Gray shaded area shows actual time of infusion.
Figure is a modified reproduction from reference 26, used with permission under the author reuse policy of the publisher. SEM, standard error of the
mean; UPDRS, Unified Parkinson’s Disease Rating Scale.
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strips were done every 30 minutes until after the infu-
sion was completed and clinical measures returned to
the preinfusion baseline values for 2 consecutive assess-
ments, with a minimum of 3 hours of monitoring after
initiation of infusion. Blood sampling for plasma levo-
dopa concentrations was done immediately prior to
infusion, then at 30-minute intervals for 3 hours, then
at 1-hour intervals until the end of clinical monitoring.
Primary outcome measures were UPDRS III (motor
section of the UPDRS) score29 and finger-tapping speed,
the number of times the patient could, in 1 minute, alter-
nately tap 2 counters placed 20 cm apart using the index
finger of their more affected arm.30 Finger-tapping speed
is a validated measure of bradykinesia in PD.31,32 Sec-
ondary outcome measures included dyskinesia and
plasma levodopa levels. Dyskinesia was assessed using a
modified version of the previously developed dyskinesia
rating scale,30 with a score of 0 (absent) to 4 (incapacitat-
ing) for 7 body parts (each limb, face, neck, and trunk)
for a maximum possible score of 28. Safety was evalu-
ated by assessment of incidence of electrocardiogram
changes (to detect arrhythmias), adverse events (AEs),
and vital sign abnormalities.
Statistical Analysis
UPDRS III scores, finger-tapping speeds, and dyskine-
sia scores are presented as change from baseline over
time (time-action curves). Because there was some
improvement in off-medication scores after gene ther-
apy, baselines for all time-action curves were the mean
of the −1 hour, −0.5 hour, and 0 hour time points from
both pre–VY-AADC01 days (ie, the mean of the
6 preinfusion, pre–VY-AADC01 values). After the start
of levodopa infusion, UPDRS III scores greater than
baseline and finger-tapping speeds less than baseline
were truncated to 0. As clinical responses may worsen
to below baseline after levodopa wearing-off33 and the
duration of response to infused levodopa varied among
participants, including scores below baseline as a result
of this off phenomenon could have obscured the tail
end of the overall mean response. To avoid this, we
truncated such scores, in alignment with previous levo-
dopa challenge studies.27 Area under the curve (AUC)
values were determined from time-action curves.
Temporal aspects of IV levodopa response were mea-
sured in 3 ways: change from baseline at 30 minutes
after start of infusion (for UPDRS III scores, finger-
tapping speeds, and dyskinesia rating scores), linearly
extrapolated time to 30% reduction in score (latency to
onset, UPDRS III only), and duration of ≥30% reduc-
tion in score (UPDRS III only). For all measures of
timing, baseline was the value at the 0 hour time point
(initiation of levodopa infusion) on the day of assess-
ment. A 30% change in UPDRS III as a threshold for
response has been employed in a previous trial of a PD
medication.34
Peak responses were the minimum absolute values for
UPDRS III scores and the maximum absolute values for
finger-tapping speed and dyskinesia rating scale scores.
Data are reported as mean  standard error of the mean.
Results
Participants
Of the 15 patients enrolled in PD-1101, 13 partici-
pated in this substudy: all 5 patients from cohort 1, all
5 patients from cohort 2, and 3 of 5 patients from
cohort 3. A total of 2 patients from cohort 3 were
unable to travel to OHSU. Demographics and baseline
characteristics for participants in the substudy were
generally well balanced between cohorts, although
UPDRS III scores on medication were lower in cohort
1 than the other 2 cohorts, and Unified Dyskinesia Rat-
ing Scale scores were higher in cohort 3 than the other
2 cohorts (Supplementary Table S1). One participant in
cohort 1 did not achieve on status in response to
threshold-dose IV levodopa at the pre–VY-AADC01
visit and refused several assessments. Last observation
carried forward values were imputed for missing data
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FIG. 2. Time to 30% change in UPDRS III scores (A) and duration of
≥30% UPDRS response (B) after threshold and suprathreshold IV levo-
dopa infusion pre– and post–VY-AADC01 administration. IV, intrave-
nous; SEM, standard error of the mean; UPDRS, Unified Parkinson’s
Disease Rating Scale.
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Clinical Outcomes
The effects of VY-AADC01 on the UPDRS III scores
were most prominent with the threshold (lower dose)
levodopa infusions. Magnitude and duration of responses
to threshold levodopa were increased after gene therapy
in all cohorts, as shown by time-action curves (Fig. 1).
The 168% increase in mean AUC and marked improve-
ment in peak response (Supplementary Table S2)
supported the time-action curve findings. UPDRS III
responses were more rapid in onset and more persistent
after gene therapy: time to 30% reduction (latency of
onset) was shortened and duration of ≥30% response
was prolonged in all cohorts (Fig. 2). Change from base-
line at 30 minutes was also increased, further supporting
a more rapid response. For suprathreshold levodopa infu-
sions, time-action curves showed that the gene therapy
increased the duration of UPDRS III responses in all
cohorts but increased the magnitude only in
cohort 2. AUC increased by 67%, with minimal improve-
ment in peak response. Latency of onset was shortened in
cohorts 2 and 3, and there were modest increases in dura-
tion of ≥30% response in each cohort. Change from base-
line at 30 minutes also increased after VY-AADC01.
Finger-tapping speeds, an independent measure of
bradykinesia, also improved after AADC gene delivery.
Time-action curves for finger-tapping in the threshold
and suprathreshold condition largely mirrored those for
UPDRS III scores (Fig. 3). Large increases in AUC were
observed after VY-AADC01 for both levodopa doses
(threshold, 162%; suprathreshold, 113%), whereas
increases in peak response and change from baseline at
30 minutes were modest (Supplementary Table S2).
Not surprisingly, dyskinesia scores with levodopa
infusion were higher after gene therapy (Fig. 4). The
duration of dyskinesia was longer post–VY-AADC01
administration in all cohorts in the suprathreshold con-
dition. Mean overall AUC for dyskinesia increased by
208% and 72% in the threshold and suprathreshold
levodopa conditions, respectively. There were also
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FIG. 3. Change from baseline in finger-tapping speed over time during and following threshold and suprathreshold infusions of intravenous levodopa
pre– and post–VY-AADC01 administration. Increase in finger-tapping speed represents improvement. Gray shaded area shows actual time of infusion.
SEM, standard error of the mean.
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infusion after gene therapy as well as in change from
baseline at 30 minutes (Supplementary Table S2).
After VY-AADC01 administration, there were trends
toward improvement in off-medication UPDRS III
scores and finger-tapping speeds at baseline (ie, when
the patients had been without levodopa and other anti-
parkinsonian medications overnight; Fig. 5; also note
apparent baseline shifts in Figs. 1 and 3).
Mean plasma levodopa concentration profiles during
and after the levodopa infusions were similar before and
after VY-AADC01 treatment (Supplementary Fig. S1).
Safety
AEs were reported in 5 participants during levodopa
challenges; 5 had AEs during the pre–VY-AADC01
levodopa challenge, and 2 also had AEs during the
post–VY-AADC01 levodopa infusions. All AEs were
mild or moderate in severity (Supplementary Table S3).
No arrhythmias were detected with electrocardiogram
monitoring. Safety findings from the parent PD-1101
study have been reported previously.26
Discussion
VY-AADC01 gene therapy was designed to increase
conversion of levodopa to dopamine in the putamen
of patients with PD. The changes in 18F-fluoro-L-
dihydroxyphenylalanine positron emission tomography
signal observed after gene therapy administration in the
parent study confirmed increased AADC enzymatic
activity.26 The increased AADC activity was associated
with a consistent increase in clinical response to IV levo-
dopa in this substudy. Enhanced responses to levodopa
infusion were not the result of increased peripheral levo-
dopa, as there were no differences in plasma levodopa
concentrations during IV challenge before and after
VY-AADC01 administration (Supplementary Fig. S1).
This gene therapy particularly augmented the response
to low-dose levodopa infusions, suggesting that effica-
cious dopamine levels may be reached at lower levodopa
doses. This observation is consistent with previous stud-
ies in NHPs with MPTP-induced parkinsonism, in which
AAV2-hAADC gene therapy enhanced clinical responses
to low doses of levodopa that were ineffective in parkin-
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FIG. 4. Change from baseline in dyskinesia rating scale scores during and following threshold and suprathreshold infusions of intravenous levodopa
pre– and post–VY-AADC01 administration. Increase in dyskinesia rating scale score indicates worsened dyskinesia. Gray shaded area shows actual
time of infusion. SEM, standard error of the mean.
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The changes in UPDRS III scores and finger-tapping
speeds, particularly in the suprathreshold levodopa condi-
tion, were driven primarily by decreased latency to effect
onset and increased effect duration, with a minor contri-
bution from increases in peak responses. These findings
align with previous evidence that increasing plasma levo-
dopa concentrations above minimally effective levels
enhances the duration of improvements in finger-tapping
and walking speed, but not the magnitude of such
responses.35 In an evaluation of levodopa therapeutic
windows, the magnitude of motor function responses to
IV levodopa plateaued at approximately 150% of thresh-
old dose in patients with advanced PD, whereas the dura-
tion of responses continued to increase at doses 300%
above threshold.36 A possible explanation for this discon-
nect between magnitude and duration of effect may be
that dopamine synthesis sufficient to saturate dopamine
receptors is reached at some threshold levodopa dose,
and levodopa in excess of this threshold only prolongs
the duration of response. After VY-AADC01 gene ther-
apy, this threshold level of putaminal dopamine may be
reached with lower levodopa doses because of the
enhanced local conversion of levodopa to dopamine.
Dyskinesia and antiparkinsonian benefits generally go
hand in hand in people with PD who have a fluctuating
response to levodopa. Therefore, an increase in dyskine-
sia that paralleled the increase in clinical response was
not unexpected.36-38 In the parent study, dyskinesias did
increase post–VY-AADC01 administration as
anticipated with the predicted mechanism of action;
these dyskinesias proved to be transient and uniformly
responsive to reductions in antiparkinsonian medications
and ultimately were not worse than before gene
therapy.26
Anunanticipatedfinding in this substudywas that baseline
UPDRS III scores and finger-tapping speeds improved after
VY-AADC01 administration. This observation is consistent
with unpublished findings in NHPs with MPTP-induced
parkinsonism in which clinical rating scores gradually
improved after AADC gene therapy in the absence of levo-
dopa treatment (K.S. Bankiewicz, personal communication,
March 2019). The present findings are also in agreement
with improvements in off-medication UPDRS III scores
observed in previous clinical studies of AAV2-hAADC22,24
and in the parent study.26 A possible explanation for this
improvement in the off-medication condition is increased
synthesis of dopamine from endogenous levodopa. In phar-
macokinetic/pharmacodynamic models of levodopa action
in PD, the inclusion of low levels of endogenous levodopa
production as a factor improved predictions of actual
patient-derived data.39
A limitation of this substudy is the potential for a placebo
effect following gene therapy administration; placebo
effects are particularly prominent after neurosurgical inter-
ventions in PD.40 In addition, PD-1101 had small cohort
sizes that were not powered for efficacy assessments or for
between-cohort comparisons. A lingering question is
whether the administration of IV levodopa at a clinical
research center translates to the clinical setting with oral
levodopa and the use of other antiparkinsonian medica-
tions. The findings of this substudy predicted that anti-
parkinsonian medication needs would be decreased,
consistent with the actual reductions in medication use by
these patients reported in the parent study.
In conclusion, the IV levodopa paradigm provided a
blinded and more objective examination of the effects
of VY-AADC01 gene therapy on responses to levodopa
in PD. The results were consistent with the clinical
responses in the patients and confirm and extend the
findings in NHPs. The substudy provides further evi-
dence that AADC gene therapy may provide meaning-
ful benefits to people with PD and supports further
clinical development of VY-AADC01.
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